secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-08-27T23:59:59+00:00
Accession:  0001641172-25-025688
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir reports in vitro data: Telomir-1 inhibits UTX and modestly targets Tankyrases
--------------------------------------------------------------------------------

- Telomir-1 potently inhibits UTX (KDM6A), a histone demethylase linked to cancer, aging, neurodegeneration.
- Low-level inhibition of Tankyrases (PARP5A/B) may disrupt Wnt/β-catenin pathway without telomere shortening risks.
- Selectivity vs GCN5L2 suggests cleaner safety margin vs other epigenetic drugs.
- Prior in vivo data showed reactivation of tumor suppressors STAT1/TMS1 and telomere elongation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225025688/0001641172-25-025688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225025688/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-025688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer